Abstract
<b><i>Introduction:</i></b> Automatic implantable cardioverter-defibrillators (AICDs) for the primary prevention of sudden cardiac death have become standard care for patients with systolic heart failure (sHF) and ejection fraction ≤35%. While the prevalence of sHF and rates of hospitalization are higher in men, one would expect equivalent rates of implantation in women. <b><i>Methods:</i></b> We used the Healthcare Cost and Utilization Project’s National Inpatient Sample (NIS) from 2009 to 2018 to identify patient visits with sHF and AICD implantation. The comorbidities and outcomes were compared based on gender. <b><i>Results:</i></b> There were 15,247,854 inpatient admissions for sHF, of which 60.3% were males (95% CI: 60.1%–60.4%) and 39.8% females (95% CI: 39.7%–39.9%). Approximately 2% of patients (294,726) underwent the insertion of an AICD for primary prevention: 72.3% males (95% CI: 71.9%–72.7%) and 27.72% females (95% CI: 27.3%–28.1%). There was no significant difference in age (<i>p</i> = 0.29), length of stay (<i>p</i> = 0.09), and inpatient mortality (<i>p</i> = 0.18). <b><i>Conclusion:</i></b> In this study, women accounted for approximately 40% of patients admitted with the diagnosis of sHF; however, they accounted for less than 30% of patients who underwent the insertion of an AICD. Further research is needed to better understand this gender disparity and identify reasons for the lower rates of AICD placement in women.